Dr. Jennifer Jane Gile, MD

Dr. Gile practices at Willamette Valley Cancer Institute and Research Center in Eugene, Oregon.

Dr. Gile's NPI, 1336609288, was assigned on March 25, 2019. Dr. Gile graduated from University of Colorado School of Medicine, Denver in 2019. Dr. Gile holds Minnesota license 67744.

Dr. Gile's primary practice is Willamette Valley Cancer Institute and Research Center, at 520 Country Club Pkwy, Eugene, OR 97401 in Lane County. The practice phone is (541) 683-5001.

Dr. Gile's primary practice is Willamette Valley Cancer Institute and Research Center in Eugene, Oregon. Dr. Gile is also affiliated with Mayo Clinic Hospital, Saint Marys Campus. The medical group on file is Willamette Valley Cancer Institute & Research Center. Dmand AI also links Dr. Gile to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gile practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Gile's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Gile is licensed in Minnesota.

CMS data shows 185 Medicare services from Dr. Gile across 5 procedure codes in 2024, all of them office visits, for 132 Medicare patients. Medicare paid $19,553 for them. Every service was in an office.

CMS counts 132 Medicare patients who saw Dr. Gile in 2024. The largest group is 65 to 74, with 59 patients. 67% of them have high blood pressure, and 63% have high cholesterol. 14% are also on Medicaid. Their average risk score is 2.55, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Gile's median patient age at 68, with 55% women.

In 2024, Dr. Gile wrote 223 Medicare Part D claims for 54 patients. 81% of them were for generic drugs. CMS names the drug for 66 of them, across 5 drugs with 11 or more claims each, at $143,290 in total drug cost. In 2023, CMS named 29 claims across 2 drugs.

Dr. Gile accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Gile as offering telehealth.

Dmand AI links 21 papers to Dr. Gile, published from 2020 to 2025. 2021 was the busiest year, with 4. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Magnesium and Neuroendocrine Tumors. Dr. Gile has published most often in Oncologist. Dr. Gile's most frequent co-authors are Zhaohui Jin, MD, Thomas E. Witzig, MD and Gordon J. Ruan, MD.

CMS Open Payments shows 2 general payments to Dr. Gile from 2 drug and device companies from 2021 to 2025. Grants make up the largest share, 98% of the total. Merck Sharp & Dohme Corporation paid the most, $1,000.

Dr. Gile graduated from University of Colorado School of Medicine, Denver in 2019.